Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma [6]

Bone Marrow Transplantation

Volumn 36, Issue 3, 2005, Pages 271-273

  Wulf, G G ^a   Hasenkamp, J ^a   Jung, W ^a   Chapuy, B ^a   Truemper, L ^a   Glass, B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MYCOPHENOLIC ACID; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FEASIBILITY STUDY; FOLLOW UP; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LETTER; MORTALITY; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REMISSION; SALVAGE THERAPY; SIDE EFFECT; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; DISEASE PROGRESSION; GLYCOPROTEINS; HUMANS; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 23744450064     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705036     Document Type: Letter

References (13)

1. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998; 92: 76-82.
2. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
3. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Enblad G, Hagberg H, Erlanson M et al. A pilot study of atemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920-2924.
5. Schetelig J, Fetscher S, Reichle A et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88: 1272-1278.
6. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplantation 2000; 25: 1021-1028.
7. Bishop MR, Hou JWS, Wilson WH et al. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant 2003; 9: 162-169.
8. Glass B, Nickelsen M, Dreger P et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplantation. 2004; 34: 391-397.
9. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
10. Weidmann E, Boehrer S, Chow KU et al. Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine. Onkologie 2001; 24: 162-164.
11. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1 H. Blood 2001; 98: 1721-1726.
12. Chanan-Khan A, Islam T, Alam A et al. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with Anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymph 2004; 45: 1673-1675.
13. Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172-2176.